Levis, M. J., Erba, H. P., Montesinos, P., Vrhovac, R., Patkowska, E., Kim, H.-J., … Perl, A. E. (2023). QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 23, pp. S272–S272).

Levis, Mark J., Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Hee-Je Kim, Pavel Zak, et al. “QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS).” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23:S272–S272, 2023.

Levis MJ, Erba HP, Montesinos P, Vrhovac R, Patkowska E, Kim H-J, et al. QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS). In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S272–S272.

Levis, Mark J., et al. “QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS).” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 23, 2023, pp. S272–S272.

Levis MJ, Erba HP, Montesinos P, Vrhovac R, Patkowska E, Kim H-J, Zak P, Wang P-N, Rohrbach JEC, Chang KCN, Hanyok J, Liu L, Kamel YM, Lesegretain A, Cortes J, Sekeres MA, Dombret H, Amadori S, Wang J, Schlenk RF, Perl AE. QuANTUM-First Trial: FLT3-Internal Tandem Duplication (FLT3-ITD)-Specific Measurable Residual Disease (MRD) Clearance Is Associated With Improved Overall Survival (OS). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2023. p. S272–S272.